Chimeric Monomer-Dimer Hybrid Proteins for Epithelial Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chimeric proteins comprising biologically active molecules linked to immunoglobulin constant regions face limitations in transport across epithelial barriers due to high molecular weight and steric hindrance, leading to reduced efficacy and increased self-aggregation.
Innovation Solution
Development of monomer-dimer hybrid chimeric proteins, where only one chain contains a biologically active molecule and the other chain comprises a portion of an immunoglobulin constant region without the biologically active molecule, enhancing transport efficiency and reducing self-aggregation by minimizing molecular weight and steric hindrance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If chimeric proteins comprise biologically active molecules linked to immunoglobulin constant regions to enhance stability and serum half-life, then therapeutic efficacy is improved, but molecular weight increases causing reduced transport efficiency across epithelial barriers
Solution Approach 1:
The chimeric protein is segmented into two distinct polypeptide chains: Chain 1 contains the biologically active molecule linked to an immunoglobulin constant region, while Chain 2 contains only the immunoglobulin constant region. This segmentation creates a hybrid structure that reduces overall molecular weight and steric hindrance while preserving the essential FcRn binding functionality for extended serum half-life.
2Quantity of substance
If chimeric proteins are designed as homodimers with two biologically active molecules to increase therapeutic potency, then efficacy is enhanced, but steric hindrance increases reducing accessibility to target cells
Solution Approach 1:
The chimeric protein adopts an asymmetric heterodimer structure rather than a symmetric homodimer. Chain 1 (with biologically active molecule) and Chain 2 (without biologically active molecule) have different compositions and functions. This asymmetry reduces steric hindrance and improves accessibility to target cells while maintaining therapeutic potency through the single biologically active molecule in Chain 1.
Data Source
AI summary
The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.